Interpreting the results of cost-effectiveness studies.

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  Paul B Ginsburg,et al.  High and rising health care costs. , 2008, The Synthesis project. Research synthesis report.

[3]  Laura Mauri,et al.  Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. , 2008, Journal of the American College of Cardiology.

[4]  T. Ferris,et al.  Options for slowing the growth of health care costs. , 2008, The New England journal of medicine.

[5]  S Bryan,et al.  The use of economic evaluations in NHS decision-making: a review and empirical investigation. , 2008, Health technology assessment.

[6]  S. Bryan,et al.  Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. , 2008, Health technology assessment.

[7]  Mark Nuijten,et al.  Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  Mark S Roberts,et al.  The value of medical spending in the United States. , 2006, The New England journal of medicine.

[9]  Merrill Goozner,et al.  The value of medical spending in the United States. , 2006, The New England journal of medicine.

[10]  A. Ward,et al.  Cost-effectiveness of cardiac resynchronization therapy. , 2006, Journal of the American College of Cardiology.

[11]  Sandeep Vijan,et al.  The value of medical spending in the United States, 1960-2000. , 2006, The New England journal of medicine.

[12]  G. Stone,et al.  Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. , 2006, Journal of the American College of Cardiology.

[13]  A. Tsiatis,et al.  Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.

[14]  Dan Greenberg,et al.  Trends in the measurement of health utilities in published cost-utility analyses. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Alvin I Mushlin,et al.  The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. , 2006, Journal of the American College of Cardiology.

[16]  M. Hlatky.  Cost effectiveness of cardiac resynchronization therapy. , 2005, Journal of the American College of Cardiology.

[17]  D. Kass,et al.  Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.

[18]  Sue J Goldie,et al.  Cost-effectiveness of cervical-cancer screening in five developing countries. , 2005, The New England journal of medicine.

[19]  Paul G Shekelle,et al.  Consequences of health trends and medical innovation for the future elderly. , 2005, Health affairs.

[20]  Thomas Bodenheimer,et al.  High and Rising Health Care Costs. Part 2: Technologic Innovation , 2005, Annals of Internal Medicine.

[21]  S. Yusuf,et al.  Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. , 2005, Journal of the American College of Cardiology.

[22]  P. Heidenreich,et al.  A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin Alone , 2005, Annals of Internal Medicine.

[23]  S. Murphy,et al.  Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. , 2004, Journal of the American College of Cardiology.

[24]  Ameet Bakhai,et al.  Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial , 2004, Circulation.

[25]  S. Tunis.  Why Medicare has not established criteria for coverage decisions. , 2004, The New England journal of medicine.

[26]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[27]  D. Mark,et al.  Medical economics and the assessment of value in cardiovascular medicine: Part I. , 2002, Circulation.

[28]  D. Mark.  Visualizing cost-effectiveness analysis. , 2002, JAMA.

[29]  G. Larsen,et al.  Cost-Effectiveness of the Implantable Cardioverter-Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmias: Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy , 2002, Circulation.

[30]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[31]  G. Sanders,et al.  Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction , 2001, Annals of Internal Medicine.

[32]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[33]  M C Weinstein,et al.  Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of Patients , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  B A Craig,et al.  Uncertainty in Decision Models Analyzing Cost-Effectiveness , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[35]  A I Mushlin,et al.  The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. , 1998, Circulation.

[36]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[37]  A Briggs,et al.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.

[38]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[39]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[40]  K E Willard,et al.  Probabilistic Analysis of Decision Trees Using Monte Carlo Simulation , 1986, Medical decision making : an international journal of the Society for Medical Decision Making.

[41]  G. Torrance.  Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[42]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[43]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[44]  M. T. Smolkin.  Medicare and cost-effectiveness analysis. , 2006, The New England journal of medicine.

[45]  J.,et al.  Markov Models in Medical Decision Making : A Practical Guide , 2006 .

[46]  J. Ware,et al.  Equivalence trials. , 1997, The New England journal of medicine.

[47]  Epstein.  The Multicenter Automatic Defibrillator Implantation Trial. , 1997, Journal of cardiovascular pharmacology and therapeutics.

[48]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[49]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .